Abstract
Objective To evaluate clinical curative effect of levosimendan therapy on patients with refractory heart failure. Methods A total of 84 patients with refractory heart failure were randomly and equally divided into le-vosimendan group and routine treatment group. Both groups received routine antiheart failure medication, levosimendan group received levosimendan therapy while routine treatment received milrinone injection therapy additionally. Changes of left ventricular ejection fraction(LVEF)and plasma level of N terminal pro type B natriuretic peptide(NT-proB-NP)were compared between two groups before and after treatment. Results Compared with routine treatment group, there were significant increase in total effective rate of LVEF［（0.36±0.18)%vs.(0.42±0.36)%］, and in NT-proBNP［（975.14±247.01)ng／mL vs.(832.14±224.78)ng／mL］. The effect before and after treatment of levosi-mendan group were more obviously(NT-proBNP：t＝2.3-230.2,P＜0.02;LVEF：t＝2.29-215.2,P＜0.01). Conclusion Levosimendan can significantly improve heart function, decrease NT-proBNP level in patients with refractory heart failure. Key words: Levosimendan，Heart failure, Milrinone injection, N terminal pro type B natriuretic peptide, Left ventricular ejection fraction
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
